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Introduction 
The Economic Botany Collection at the Royal Botanic 
Gardens, Kew contains the Royal Pharmaceutical Society’s 
19th Century educational Materia Medica cabinets (Fig. 2,3). 
Within these, Eucalyptus spp. contributes the largest section 
of essential oil bottles (117 specimens; 80 species) 
demonstrating the depth of historical interest in its medicinal 
properties[1]. However, only three species (E.globulus, 
E.smithii & E.polybractea) are now accepted medicinally [2,3] 
leading the question of how this medicine developed. 
Historical medical collections such as this contain a wealth of 
unexplored objects and documentation that may reveal 
sources of medicine worth revisiting[4]. With the rise in 
antibiotic resistance globally, revisiting Eucalyptus in 
particular may prove a valuable exercise in finding an 
effective, accessible and sustainable medicine[5]. 
 
Aim
An exploration of 150 years of artefacts and paper scientific 
records (n=1,557) to map the development and acceptance 
of Eucalyptus into conventional medicine. 
 
Methods 
To analyse both numeric and textual data, thematic content 
analysis was used on the following data: 
•  The oil bottles from the collection, their packaging and 
related documentation 
•  Articles & Correspondence from the Pharmaceutical 
Journal (PJ), British Medical Journal (BMJ) and The 
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Results 
‘Discovery’ & Introduction to Europe 
•  Eucalyptus was first ‘discovered’ in Botany Bay, Australia 
by Sir Joseph Banks, on Captain Cook’s first voyage of 
discovery in 1770 
•  Surgeons on the First Fleet in 1788 used E.piperita for 
wound healing, based on organoleptic properties similar 
to English Peppermint 
•  Ferdinand von Mueller, Director of the Melbourne Botanic 
Gardens promoted its antiseptic use possibly based on 
Australian First Peoples’ use  
•  E.globulus Seeds originally sent to Europe for timber 
agronomy 
First phase in the west: anti-malarial use  
•  The European Eucalyptus forests gained a reputation for 
clearing malarial districts of ‘noxious odours’ with their 
‘fragrant emanations’ 
•  This use soon fell out of favour with developments in 
scientific knowledge of germ theory and the discovery of 
the mosquito vector 
•  It was realised that Eucalyptus drained marshy sites and 
interrupted the mosquito life-cycle 
 
Development as an antiseptic 
•  Sir Joseph Lister, pioneer of antiseptic surgery in 1881 
advocated the use of the essential oil as a disinfectant 
and in wound dressings 
•  Publications on this use rose and were maintained for 
other antiseptic uses, including infectious diseases (See 
Fig.1) and as an inhalation for colds, ‘flu and 
Tuberculosis 
Problems  
•  Political and economical supply ‘battles’ between 
European-grown species and the wider variety of 
potentially more medicinal and higher oil yield species in 
Australia 
•  Arguments over the best species and key active 
constituent in early chemistry development 
•  Chemical tests confounded by un-authenticated oils 
contaminated with other species at the distilling stage 
(Fig.6) 
Fall from use 
•  Supply interruption during the First World War prevented 
further investigation and widespread use 
•  Discovery of Antibiotics after World War 2 further impacted 
on use of  plant based antimicrobials 
Conclusion 
The translation of this Australian botanical therapeutic into 
western medicine was not always a straightforward process. 
The official species settled on was not necessarily the most 
medicinal. There was a definite tension between quality and 
supply; in the end the most easily produced species 
dominated pharmacy. Because of this, the full potential of 
Eucalyptus may not have been explored. There may yet be 
some hidden value in the ‘forgotten’ (700+) species to 
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Figure 2: (L) Royal Pharmaceutical Society’s Materia Medica cabinet & a close up of one of the Euc
alyptus essential oil drawers; Figure 3: (R) A 19th Century essential oil bottle from the drawer.  
Figure 5: (L) E.globulus botanical drawing; Figure 6: (R) An essential oil distillery, 
Australia, circa 1850. Picture credits: Natural History Museum  
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